InflaRx Announces Initiation of its Commitment Program for GOHIBIC(vilobelimab) to Help Broaden Access for Eligible Patients

• InflaRx to cover costs of GOHIBIC for patients who are treated in line with its Emergency Use Authorization (EUA) but do not survive.
• InflaRx is determined to support broader access to GOHIBIC for eligible patients.

ANN ARBOR, Mich., Jan. 25, 2024 (GLOBE NEWSWIRE) -- InflaRx Pharmaceuticals Inc., a subsidiary of InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced today that the Company has launched The InflaRx Commitment Program (Commitment Program). Pursuant to the Commitment Program, the cost of GOHIBIC (vilobelimab) will be refunded for up to six (6) administered inpatient doses (the full treatment course) to institutions that meet the eligibility requirements*, for patients who were administered GOHIBIC in line with its EUA and who died due to COVID-19 in the intensive care unit.

In April 2023, the U.S. Food and Drug Administration (FDA) issued an EUA for GOHIBIC for the treatment of COVID-19 in hospitalized adults when initiated within 48 hours of the patient receiving invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO). While GOHIBIC has been FDA authorized, it is not FDA approved for this use.

The Commitment Program is designed to encourage medical facilities across the United States to stock GOHIBIC, since the initiation of treatment is time critical, and to ultimately provide the opportunity for patients to access this potentially life-saving therapy.

According to the Centers for Disease Control, there has been a recent increase in COVID-19 fatality rates, with reported deaths related to this disease in the range of 1,500 deaths per week in the U.S.¹

Christian Sandrock, M.D., M.P.H., FCCP, Division Vice Chair of Internal Medicine, Director of Critical Care, Professor of Medicine, UC Davis Health, said: “Once a patient with COVID-19 reaches the point of intubation, there are extremely limited treatments available outside of supportive care and mechanical ventilatory support. With COVID-19 deaths again on the rise, it is critical that doctors have access to more therapies to help save the lives of these patients, particularly for those that have progressed to require mechanical ventilation. With the emergency use authorization of GOHIBIC, the FDA recognized a critical unmet need and provided those of us on the frontlines, fighting this disease, an important new option which has been specifically developed as a potentially life-saving therapy for these sickest patients.”